Special Issue "Prodrugs"
A special issue of Pharmaceutics (ISSN 1999-4923).
Deadline for manuscript submissions: closed (28 February 2013)
Prof. Dr. Barbara R. Conway
Professor of Pharmaceutics, School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UK
Phone: +01484 472347
This special issue will focus on prodrug strategies to address formulation, delivery, and toxicity limitations of drug molecules.
Prodrugs are pharmacological substances administered in an inactive (or less than fully active) form which are subsequently converted into active compounds through normal metabolic processes. The classical prodrug approach involves altering physico-chemical, biopharmaceutical or pharmacokinetic properties to maximize the amount of active drug reaching its site of action and this continues to be a useful strategy. Such approaches include increasing bioavailability (by optimization of aqueous solubility and lipophilicity) and influencing duration of pharmacological effects by increasing stability or decreasing first-pass effects. The prodrug approach can also be adopted to improve organoleptic properties and to improve how selectively the drug interacts with cells or processes that are not its intended target, reduces adverse or unintended side-effects.
Prodrug technologies are becoming more important for addressing undesirable properties associated with modern potential drugs and are being considered in the early stages of the drug development process. Computational approaches can consider using a design of linkers with drugs that have poor bioavailability to release the parental drugs in programmable manner and improve their bioavailability. Targeting approaches of coupling of low-molecular weight drugs to synthetic polymers such as PEG or serum proteins through a cleavable linker are also gaining popularity. Selective activation of prodrugs in tumour tissues can also be achieved using gene-directed enzyme prodrug therapy (GDEPT), virus-directed enzyme prodrug therapy (VDEPT), and antibody-directed enzyme prodrug therapy (ADEPT). Any of these aspects of prodrug design and application are welcome in this issue.
Prof. Dr. Barbara R. Conway
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- drug release
- drug delivery
- physicochemical characteristics
- drug targeting
- oral administration
- tumour targeting
- drug delivery
- poly (ethylene glycol) prodrugs
- Monoclonal Antibody Drug Conjugates
Pharmaceutics 2013, 5(2), 220-231; doi:10.3390/pharmaceutics5020220
Received: 28 February 2013; in revised form: 21 March 2013 / Accepted: 22 March 2013 / Published: 2 April 2013| Download PDF Full-text (417 KB) | Download XML Full-text
Article: Design, Synthesis and in Vitro Degradation of a Novel Co-Drug for the Treatment of Psoriasis
Pharmaceutics 2013, 5(2), 232-245; doi:10.3390/pharmaceutics5020232
Received: 1 February 2013; in revised form: 1 April 2013 / Accepted: 10 April 2013 / Published: 17 April 2013| Download PDF Full-text (381 KB) | Download XML Full-text
Article: Preclinical Absorption, Distribution, Metabolism, and Excretion of an Oral Amide Prodrug of Gemcitabine Designed to Deliver Prolonged Systemic Exposure
Pharmaceutics 2013, 5(2), 261-276; doi:10.3390/pharmaceutics5020261
Received: 19 February 2013; in revised form: 26 April 2013 / Accepted: 2 May 2013 / Published: 8 May 2013| Download PDF Full-text (353 KB) | Download XML Full-text
Pharmaceutics 2013, 5(2), 277-293; doi:10.3390/pharmaceutics5020277
Received: 4 February 2013; in revised form: 29 April 2013 / Accepted: 3 May 2013 / Published: 10 May 2013| Download PDF Full-text (682 KB) | Download XML Full-text
Communication: Design and Exploratory Neuropharmacological Evaluation of Novel Thyrotropin-Releasing Hormone Analogs and Their Brain-Targeting Bioprecursor Prodrugs
Pharmaceutics 2013, 5(2), 318-328; doi:10.3390/pharmaceutics5020318
Received: 21 March 2013; in revised form: 7 May 2013 / Accepted: 10 May 2013 / Published: 22 May 2013| Download PDF Full-text (210 KB) | Download XML Full-text
Last update: 8 May 2013